ClinicalTrials.gg
RecruitingNCT06046612Updated Sep 21, 2023

Empagliflozin for Peripheral Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction

A Phase 4 interventional study of Participants receive 10mg Empaglifozin once daily on prescription from their treating physician. This is not an intervention in this trial, but part of their normal HFpEF treatment in Heart Failure With Preserved Ejection Fraction and Microvascular Dysfunction, sponsored by Maastricht University Medical Center. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-21.

Sponsored by Maastricht University Medical Center · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2024, 2 years 3 months ago, but the record still lists the study as recruiting.
  • Started Feb 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
48
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies testing empagliflozin in Heart Failure — 16 open to participants now, 22 under way, 7 of them phase 3. empagliflozin · Heart Failure.

Planned enrollment
43rd of 51
48 · median 90
Started
2023
with 6 others
Phase 4
16 of 51
6 open now
Primary completion
2024-08
later than 2 of 21 live
Registered
31st of 51
by date

Among the 51 studies testing empagliflozin in Heart Failure, this one is the 43rd largest by planned enrollment, is one of 7 that started in 2023, is one of 16 in phase 4, reaches primary completion later than 2 of the 21 other live ones, and was the 31st registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

16 of the 51 studies testing empagliflozin in Heart Failure are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About empagliflozin

empagliflozin: first FDA approval 2014 (JARDIANCE), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing empagliflozin in Heart Failure, or all of them as a file.
02

Study summary

The goal of this low-intervention clinical trial is to learn about the effect of the drug Empagliflozin in patients with heart failure with preserved ejection fraction.

The main questions it aims to answer are:

  • What is the effect of treatment with Empagliflozin after 3 months on peripheral microvascular function
  • Do clinical correlates for worse microvascular function exist, and thus identify patients that could possibly benefit most from empagliflozin treatment

Patients will use Empagliflozin, prescribed by their treating physician. Before the start of treatment and after 3 months they will be asked to

  • Fill out a quality of life questionnaire
  • Draw 4 tubes of blood
  • Undergo non-invasive measurement of the blood flow of the microvasculature in the forearm (using laser speckle contrast analysis)
Read the detailed description

Heart failure (HF) with preserved ejection fraction (HFpEF), is an important public health problem with a poor prognosis and many people are affected by it. Microvascular dysfunction (MVD) is thought to play an important role in this complex syndrome. MVD may lead to disease progression in HFpEF. For the past years the main focus of HFpEF treatment has been on symptom relieve and diagnosing and treating co-occurring disease, such as hypertension or diabetes. Recently, the sodium-glucose co-transporter 2 (SGLT-2) inhibitor Empagliflozin was suggested to be added to this list of treatments. This drug was proven to reduce the combined risk of cardiovascular death or HF hospitalization in HFpEF patients in the EMPEROR-PRESERVED trial. Preclinical studies have proposed an important role for microvascular function in the mechanism of action of empagliflozin in HFpEF. The microvasculature may also play an important role in the etiology of HFpEF.

The microcirculation in the skin is accessible and suitable for analysis of microvascular function. Laser speckle contrast analysis (LASCA) is a relatively new and non-invasive analysis that measures the blood flow in the skin microvasculature using several stimuli.

In HFpEF patients no clinical research has been conducted to evaluate the effect of Empagliflozin on MVD, despite its seemingly important role in the HFpEF etiology. We hypothesize that empagliflozin improves microvascular function in HFpEF patients. Understanding of the effects of this important drug in the treatment of HFpEF is essential to optimize its use in this growing population. Key clinical determinants may exist that improve our ability to determine which patients at what disease stage can specifically benefit from this intervention. The patients with the strongest improvement in MVD during treatment with Empagliflozin might benefit most regarding cardiac function or wellbeing.

03

Conditions studied

  • Heart Failure With Preserved Ejection Fraction
  • Microvascular Dysfunction

Browse trials for

Keywords

  • Heart failure
  • Empagliflozin
  • Jardiance
  • microvascular disease
  • microvascular function
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • HFpEF diagnosis according to the ESC 2021 Guidelines for the diagnosis and treatment of acute and chronic heart failure Symptoms and signs of HF ≥ 50% (on any imaging modality) Objective evidence of cardiac structural and/or functional abnormalities consistent with the presence of LV diastolic dysfunction/ raised LV filling pressures, including raised natriuretic peptides (table 1) OR invasively measured pulmonary capillary wedge pressure (PCWP) of >15 mmHg (at rest) or ≥25 mmHg (with exercise) or left ventricular end diastolic pressure ≥ 16 mmhg (at rest).
  • Ability to understand and speak the Dutch language
  • Treatment with empagliflozin 10mg once daily is planned to be started by the treating physician
  • Signed

Exclusion criteria

Exclusion Criteria:

  • Unable or unwilling to sign
  • Under 18 years of age
  • to the use of empagliflozin Severe kidney disease (\< 20 ml/min) Severe liver insufficiency Recent (\<12 months) or planned major surgery (Including coronary artery bypass grafting, cardiac valve replacement) Severe acute disease (\< 12 months) (Including acute coronary syndrome, /CVA) Pregnancy
  • Use of empagliflozin or other SGLT-2 inhibitor at baseline
  • Known to empagliflozin, acetylcholine, sodium nitroprusside or insulin
  • Insulin dependent patients (Fasting conditions cause a risk of ketoacidosis in these patients).
  • Subjects currently enrolled in or has not yet completed at least 30 days since ending other device or drug study.
  • Any condition that interferes with the correct execution of the LASCA measurements (patient is unable to keep arms motionless during the measurements, any condition that does not allow disposables to be attached to the forearm skin)
  • Any other reason that makes it undesirable for patient to use empagliflozin according to the researcher / treating physician
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    heart failure with preserved ejection fraction

    Empagliflozin 10mg, tablet, once daily

    Drug: Participants receive 10mg Empaglifozin once daily on prescription from their treating physician. This is not an intervention in this trial, but part of their normal HFpEF treatment

Interventions

  • DrugEmpagliflozinStudies of EmpagliflozinEmpagliflozin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The investigational medicinal product investigated in this trial (empagliflozin) is authorised for use in the European Union by the European Medicines Agency and will be used in accordance with the terms of the marketing authorization. The treating physician (cardiologist) will determine the indication for empagliflozin use, discuss the benefits and risks with the patient, prescribe the drug, and provide follow up after starting the drug, according to normal clinical practice. The study participants are not assigned to a particular therapeutic strategy decided by the clinical trial protocol.

    Also known as: Jardiance

06

What researchers measure

Primary outcomes

  1. Cutaneous vascular conductance (CVC)

    Skin blood flow (arbitrary perfusion units, APU) is divided by the mean arterial pressure to yield the CVC.

    Time frame: Change from baseline to 3 months

Secondary outcomes

  1. baseline bloodflow and area under the curve

    as measured by LASCA

    Time frame: Change from baseline to after 3 months

  2. Serum ketone levels in mmol/L

    Serum ketone levels in mmol/L

    Time frame: Change from baseline to after 3 months

  3. EQ5D-5L questionnaire score

    index value, ranging from 1 to -0.5. a higher value is a better outcome analogue scale and single index value

    Time frame: Change from baseline to 3 months

  4. EQ5D-5L questionnaire score

    visual analogue scale, ranging from 1 to 100, a higher value is a better outcome

    Time frame: Change from baseline to 3 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Aug 2024, 18 months after the start.

Of 165 non-industry phase 4 interventional studies under Heart Failure, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 56. This study's planned 18 months is below that.

Counting every sponsor, half of 184 studies reached it within 31 months; a quarter within 21 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2023
First posted
Sep 21, 2023
StartActual
Feb 13, 2023
Primary completionEst.
Aug 13, 2024
CompletionEst.
Feb 13, 2025
Last update
Sep 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06046612
Responsible party
Sponsor
First posted
Sep 21, 2023
Start date
Feb 13, 2023
Primary completion
Aug 13, 2024 (estimated)
Completion
Feb 13, 2025 (estimated)
Last update
Sep 21, 2023

Study contacts

Sanne GJ Mourmans, Drs.
Contact
sanne.mourmans@mumc.nl
+31433871612
Vanessa PM van Empel, Dr.
Contact
vanessa.van.empel@mumc.nl

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Empagliflozin

Start the discussion